骨肉瘤
免疫系统
变色
基因组不稳定性
免疫疗法
生物
免疫检查点
佐剂
癌症研究
医学
生物信息学
免疫学
肿瘤科
遗传学
DNA损伤
DNA
作者
Maya Kansara,Michele W.L. Teng,Mark J. Smyth,David M. Thomas
出处
期刊:Nature Reviews Cancer
[Springer Nature]
日期:2014-10-16
卷期号:14 (11): 722-735
被引量:1008
摘要
For the past 30 years, improvements in the survival of patients with osteosarcoma have been mostly incremental. Despite evidence of genomic instability and a high frequency of chromothripsis and kataegis, osteosarcomas carry few recurrent targetable mutations, and trials of targeted agents have been generally disappointing. Bone has a highly specialized immune environment and many immune signalling pathways are important in bone homeostasis. The success of the innate immune stimulant mifamurtide in the adjuvant treatment of non-metastatic osteosarcoma suggests that newer immune-based treatments, such as immune checkpoint inhibitors, may substantially improve disease outcome.
科研通智能强力驱动
Strongly Powered by AbleSci AI